![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis to Supply Leqvio to the UK’s National Health Service
Novartis to Supply Leqvio to the UK’s National Health Service
![Novartis building](https://www.fdanews.com/ext/resources/test/Drug-Images/Novartis-buliding.gif?t=1614205171&width=430)
September 2, 2021
Novartis has reached an agreement with the UK’s National Health Service to offer its potential blockbuster cholesterol-lowering drug Leqvio (inclisiran) for an undisclosed price.
The deal, which followed a cost-benefit review by the UK’s National Institute for Health and Care Excellence, will enable approximately 300,000 patients at high risk of a second cardiovascular event to be treated over three years.
Leqvio (inclisiran) is given as a 6-month maintenance dose for individuals with elevated low-density lipoprotein cholesterol who do not show an adequate response to statins.
Upcoming Events
-
21Oct